Anzemet (BioDeep_00001868351)

Main id: BioDeep_00000003120

 


代谢物信息卡片


dolasetron

化学式: C19H20N2O3 (324.1474)
中文名称: 多拉司琼
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: C1C2CC3CC(CC1N3CC2=O)OC(=O)C4=CNC5=CC=CC=C54
InChI: InChI=1S/C19H20N2O3/c22-18-10-21-12-5-11(18)6-13(21)8-14(7-12)24-19(23)16-9-20-17-4-2-1-3-15(16)17/h1-4,9,11-14,20H,5-8,10H2

描述信息

D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D012702 - Serotonin Antagonists
D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents
D005765 - Gastrointestinal Agents > D000932 - Antiemetics
D002491 - Central Nervous System Agents
Dolasetron(MDL-73147) is a serotonin 5-HT3 receptor antagonist used to treat nausea and vomiting following chemotherapy.

同义名列表

4 个代谢物同义名

dolasetron; Anzemet; MDL-73147; Dolasetron



数据库引用编号

11 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Andrea K Herndon, Jessica M Quimby, Liberty G Sieberg, Leigh Davis, Amber L Caress, Sabina Ligas, Ryan J Hansen, Luke A Wittenburg, Danial L Gustafson. Preliminary pharmacokinetics of intravenous and subcutaneous dolasetron and pharmacodynamics of subcutaneous dolasetron in healthy cats. Journal of feline medicine and surgery. 2018 08; 20(8):721-727. doi: 10.1177/1098612x17729310. [PMID: 28905667]
  • Iva Boušová, Lenka Skálová, Pavel Souček, Petra Matoušková. The modulation of carbonyl reductase 1 by polyphenols. Drug metabolism reviews. 2015; 47(4):520-33. doi: 10.3109/03602532.2015.1089885. [PMID: 26415702]
  • Yuming Hu, Shuo Chen, Jitao Chen, Guozhu Liu, Bo Chen, Shouzhuo Yao. Optimization of sample pretreatment methods for simultaneous determination of dolasetron and hydrodolasetron in human plasma by HPLC-ESI-MS. Journal of chromatographic science. 2012 Oct; 50(9):785-91. doi: 10.1093/chromsci/bms065. [PMID: 22645289]
  • Susie Xiujiang Li, Edward Pequignot, Deborah Panebianco, Paul Lupinacci, Anup Majumdar, Laura Rosen, Tuli Ahmed, Jane E Royalty, Thomas H Rushmore, M Gail Murphy, Kevin J Petty. Lack of effect of aprepitant on hydrodolasetron pharmacokinetics in CYP2D6 extensive and poor metabolizers. Journal of clinical pharmacology. 2006 Jul; 46(7):792-801. doi: 10.1177/0091270006288954. [PMID: 16809805]
  • U Breyer-Pfaff, K Nill. Carbonyl reduction of naltrexone and dolasetron by oxidoreductases isolated from human liver cytosol. The Journal of pharmacy and pharmacology. 2004 Dec; 56(12):1601-6. doi: 10.1211/0022357045020. [PMID: 15563768]
  • Peter Eisenberg, Jazmin Figueroa-Vadillo, Rosalio Zamora, Veena Charu, Julio Hajdenberg, Alan Cartmell, Alberto Macciocchi, Steven Grunberg. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer. 2003 Dec; 98(11):2473-82. doi: 10.1002/cncr.11817. [PMID: 14635083]
  • Steven M Grunberg, James M Koeller. Palonosetron: a unique 5-HT3-receptor antagonist for the prevention of chemotherapy-induced emesis. Expert opinion on pharmacotherapy. 2003 Dec; 4(12):2297-303. doi: 10.1517/14656566.4.12.2297. [PMID: 14640928]
  • M J Coppes, R Lau, L C Ingram, J T Wiernikowski, R Grant, D R Howard, M Perrotta, R Barr, E Dempsey, M L Greenberg, J M Leclerc. Open-label comparison of the antiemetic efficacy of single intravenous doses of dolasetron mesylate in pediatric cancer patients receiving moderately to highly emetogenic chemotherapy. Medical and pediatric oncology. 1999 Aug; 33(2):99-105. doi: 10.1002/(sici)1096-911x(199908)33:2<99::aid-mpo7>3.0.co;2-p. [PMID: 10398184]
  • M J Coppes, R Yanofsky, S Pritchard, J M Leclerc, D R Howard, M Perrotta, S Keays, A Pyesmany, E Dempsey, C B Pratt. Safety, tolerability, antiemetic efficacy, and pharmacokinetics of oral dolasetron mesylate in pediatric cancer patients receiving moderately to highly emetogenic chemotherapy. Journal of pediatric hematology/oncology. 1999 Jul; 21(4):274-83. doi: 10.1097/00043426-199907000-00007. [PMID: 10445889]
  • C L Lippert, D C Dimmitt, L Martin, M B Cramer, P Plezia, W F Hahne. Pharmacokinetics of intravenous dolasetron in cancer patients receiving high-dose cisplatin-containing chemotherapy. American journal of therapeutics. 1999 May; 6(3):129-35. doi: 10.1097/00045391-199905000-00003. [PMID: 10423655]
  • D C Dimmitt, M B Cramer, A Keung, T Arumugham, S J Weir. Pharmacokinetics of dolasetron with coadministration of cimetidine or rifampin in healthy subjects. Cancer chemotherapy and pharmacology. 1999; 43(2):126-32. doi: 10.1007/s002800050872. [PMID: 9923817]
  • D C Dimmitt, Y S Choo, L A Martin, T Arumugham, W F Hahne, S J Weir. Intravenous pharmacokinetics and absolute oral bioavailability of dolasetron in healthy volunteers: part 1. Biopharmaceutics & drug disposition. 1999 Jan; 20(1):29-39. doi: 10.1002/(sici)1099-081x(199901)20:1<29::aid-bdd151>3.0.co;2-s. [PMID: 10086835]
  • D C Dimmitt, Y S Choo, L A Martin, T Arumugham, W F Hahne, S J Weir. Single- and multiple-dose pharmacokinetics of oral dolasetron and its active metabolites in healthy volunteers: part 2. Biopharmaceutics & drug disposition. 1999 Jan; 20(1):41-8. doi: 10.1002/(sici)1099-081x(199901)20:1<41::aid-bdd150>3.0.co;2-g. [PMID: 10086836]
  • D C Dimmitt, A K Shah, T Arumugham, M B Cramer, C Halstenson, M Horton, S J Weir. Pharmacokinetics of oral and intravenous dolasetron mesylate in patients with renal impairment. Journal of clinical pharmacology. 1998 Sep; 38(9):798-806. doi: NULL. [PMID: 9753207]
  • C Lippert, A Keung, T Arumugham, M Eller, W Hahne, S Weir. The effect of food on the bioavailability of dolasetron mesylate tablets. Biopharmaceutics & drug disposition. 1998 Jan; 19(1):17-9. doi: 10.1002/(sici)1099-081x(199801)19:1<17::aid-bdd71>3.0.co;2-#. [PMID: 9510981]
  • D C Dimmitt, T L Hunt, A J Spalitto, M B Cramer, A K Shah, T Arumugham, W Hahne. Effect of infusion rate on the pharmacokinetics and tolerance of intravenous dolasetron mesylate. The Annals of pharmacotherapy. 1998 Jan; 32(1):39-44. doi: 10.1345/aph.17134. [PMID: 9475818]
  • K Stubbs, L A Martin, D C Dimmitt, N Pready, W F Hahne. Pharmacokinetics of dolasetron after oral and intravenous administration of dolasetron mesylate in healthy volunteers and patients with hepatic dysfunction. Journal of clinical pharmacology. 1997 Oct; 37(10):926-36. doi: 10.1002/j.1552-4604.1997.tb04267.x. [PMID: 9505984]
  • A C Keung, H Landriault, M Lefebvre, D Gossard, E E Dempsey, M Juneau, D Dimmitt, M Castles, L Roberts, J Spenard. Pharmacokinetics and safety of single intravenous and oral doses of dolasetron mesylate in healthy women. Biopharmaceutics & drug disposition. 1997 May; 18(4):361-9. doi: 10.1002/(sici)1099-081x(199705)18:4<361::aid-bdd25>3.0.co;2-i. [PMID: 9158883]
  • P Sanwald-Ducray, J Dow. Prediction of the pharmacokinetic parameters of reduced-dolasetron in man using in vitro-in vivo and interspecies allometric scaling. Xenobiotica; the fate of foreign compounds in biological systems. 1997 Feb; 27(2):189-201. doi: 10.1080/004982597240686. [PMID: 9058532]
  • J S McElvain, V J Vandiver, L S Eichemeier. Validation of a reversed-phase HPLC method for directly quantifying the enantiomers of MDL 74,156, the primary metabolite of dolasetron mesylate, in human plasma. Journal of pharmaceutical and biomedical analysis. 1997 Jan; 15(4):513-21. doi: 10.1016/s0731-7085(96)01827-4. [PMID: 8953495]
  • J Lerman, C Sims, N Sikich, R Gow, C Chin, E Dempsey, D R Howard, A C Keung. Pharmacokinetics of the active metabolite (MDL 74,156) of dolasetron mesylate after oral or intravenous administration to anesthetized children. Clinical pharmacology and therapeutics. 1996 Nov; 60(5):485-92. doi: 10.1016/s0009-9236(96)90144-7. [PMID: 8941021]
  • N D Huebert, J J Schwartz, L Zeidler, V Schwach, K D Haegele. Simultaneous measurement of dolasetron and its major metabolite, MDL 74,156, in human plasma and urine. Journal of chromatography. B, Biomedical applications. 1996 Oct; 685(2):291-7. doi: 10.1016/s0378-4347(96)00171-5. [PMID: 8953170]
  • E Dempsey, S Bourque, J Spénard, H Landriault. Pharmacokinetics of single intravenous and oral doses of dolasetron mesylate in healthy elderly volunteers. Journal of clinical pharmacology. 1996 Oct; 36(10):903-10. doi: 10.1002/j.1552-4604.1996.tb04757.x. [PMID: 8930777]
  • J Dow, G F Francesco, C Berg. Comparison of the pharmacokinetics of dolasetron and its major active metabolite, reduced dolasetron, in dog. Journal of pharmaceutical sciences. 1996 Jul; 85(7):685-9. doi: 10.1021/js960041m. [PMID: 8818990]
  • B L Ackermann, T A Gillespie, B T Regg, K F Austin, J E Coutant. Application of packed capillary liquid chromatography/mass spectrometry with electrospray ionization to the study of the human biotransformation of the anti-emetic drug dolasetron. Journal of mass spectrometry : JMS. 1996 Jun; 31(6):681-9. doi: 10.1002/(sici)1096-9888(199606)31:6<681::aid-jms344>3.0.co;2-f. [PMID: 8799303]
  • P Sanwald, M David, J Dow. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of dolasetron. Comparison with other indole-containing 5-HT3 antagonists. Drug metabolism and disposition: the biological fate of chemicals. 1996 May; 24(5):602-9. doi: . [PMID: 8723743]
  • M K Reith, G D Sproles, L K Cheng. Human metabolism of dolasetron mesylate, a 5-HT3 receptor antagonist. Drug metabolism and disposition: the biological fate of chemicals. 1995 Aug; 23(8):806-12. doi: NULL. [PMID: 7493546]
  • A Shah, R Lanman, V Bhargava, S Weir, W Hahne. Pharmacokinetics of dolasetron following single- and multiple-dose intravenous administration to normal male subjects. Biopharmaceutics & drug disposition. 1995 Apr; 16(3):177-89. doi: 10.1002/bdd.2510160303. [PMID: 7787130]
  • J Dow, C Berg. Stereoselectivity of the carbonyl reduction of dolasetron in rats, dogs, and humans. Chirality. 1995; 7(5):342-8. doi: 10.1002/chir.530070506. [PMID: 7495640]
  • P Sanwald, N D Huebert, K D Haegele. Simultaneous measurement of the major metabolites of dolasetron mesilate in human urine using solid-phase extraction and high-performance liquid chromatography. Journal of chromatography. B, Biomedical applications. 1994 Nov; 661(1):101-7. doi: 10.1016/s0378-4347(94)80054-5. [PMID: 7866538]
  • M G Kris, S M Grunberg, R J Gralla, L Baltzer, S A Zaretsky, D Lifsey, L B Tyson, L Schmidt, W F Hahne. Dose-ranging evaluation of the serotonin antagonist dolasetron mesylate in patients receiving high-dose cisplatin. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1994 May; 12(5):1045-9. doi: 10.1200/jco.1994.12.5.1045. [PMID: 8164028]
  • T A Gillespie, J A Eckstein, P Nardella, J E Coutant. Determination of dolasetron and its reduced metabolite in human plasma by GC-MS and LC. Journal of pharmaceutical and biomedical analysis. 1993 Oct; 11(10):955-62. doi: 10.1016/0731-7085(93)80055-6. [PMID: 8305600]
  • H Boxenbaum, T Gillespie, K Heck, W Hahne. Human dolasetron pharmacokinetics: II. Absorption and disposition following single-dose oral administration to normal male subjects. Biopharmaceutics & drug disposition. 1993 Mar; 14(2):131-41. doi: 10.1002/bdd.2510140205. [PMID: 8453023]
  • H Boxenbaum, T Gillespie, K Heck, W Hahne. Human dolasetron pharmacokinetics: I. Disposition following single-dose intravenous administration to normal male subjects. Biopharmaceutics & drug disposition. 1992 Dec; 13(9):693-701. doi: 10.1002/bdd.2510130907. [PMID: 1467456]